Odimma is a French biotech company with a unique approach in active personalized cancer immunotherapy.
Immunotherapy has revolutionized the treatment of many advanced cancers. Despite this amazing achievement, significant clinical benefits are still limited to 10 to 30% of patients.
Odimma believes in the future of precision medicine, and leverages recent advances in the field of immuno-oncology to amplify the efficacy of current therapies, improving lives and making each patient unique.
By harnessing the ability of the patient’s own immune system to specifically recognize non-self-targets displayed by the tumor, also called neoantigens, Odimma has designed a next-generation personalized immunization platform that brings a sustainable therapeutic solution to fight the most hard-to-treat cancers.
Carried by a team of experts and a supportive environment, we are now preparing our upcoming entry in the clinic
Location: France, Grand Est, Illkirch-Graffenstaden
Member count: 1-10
Total raised: $2.21209M
Founded date: 2017
Investors 1
| Date | Name | Website |
| 02.09.2021 | Capital Gr... | capitalgra... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 04.05.2023 | Seed | $2.21209M | - | finsmes.co... |
Mentions in press and media 3
| Date | Title | Description | Category | Author | Source |
| 04.05.2023 | France-bas... | Strasbourg, France-based biote... | - | - | vcbay.news... |
| 03.05.2023 | Odimma The... | Odimma Therapeutics, a Strasbo... | France | - | finsmes.co... |
| 17.05.2022 | ABL AND OD... | PARIS, May 17, 2022 /PRNewswir... | - | - | en.prnasia... |